/INCR
INCR Stock - InterCure Ltd.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.36-6.21%
$0.09 (-6.21%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.33
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.35 – $1.37
TARGET (TP)$1.56
STOP LOSS$1.25
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.58
52W High$1.79
52W Low$1.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $238.84M | $355.55M | $388.68M | $219.68M | $65.03M |
| Gross Profit | $30.23M | $105.09M | $155.08M | $91.13M | $31.98M |
| Gross Margin | 12.7% | 29.6% | 39.9% | 41.5% | 49.2% |
| Operating Income | $-67,208,000 | $-41,567,000 | $50.63M | $28.19M | $-38,400,000 |
| Net Income | $-67,795,000 | $-61,959,000 | $44.82M | $4.69M | $-37,231,000 |
| Net Margin | -28.4% | -17.4% | 11.5% | 2.1% | -57.2% |
| EPS | $-1.42 | $-1.36 | $0.99 | $0.12 | $-1.47 |
Company Overview
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 855.9% Upside
Now
$13
Low
$13
Average
$13
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 18th 2022 | Canaccord Genuity | Upgrade | Buy | $13 |
Earnings History & Surprises
INCRBeat Rate
0%
Last 8 quarters
Avg Surprise
-70.4%
EPS vs Estimate
Beats / Misses
0/8
Last 12 quarters
Latest EPS
$-0.22
Q2 2025
EPS Surprise History
Q2 23
-87.5%
$0.01vs$0.08
Q3 23
-40.0%
$0.03vs$0.05
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q3 2025 | Sep 1, 2025 | — | — | — | — |
Q3 2025 | Aug 20, 2025 | — | — | — | — |
Q2 2025 | May 1, 2025 | — | — | — | — |
Q2 2025 | Apr 29, 2025 | — | $-0.22 | — | — |
Q4 2024 | Oct 3, 2024 | — | $0.03 | — | — |
Q3 2024 | Aug 30, 2024 | — | $0.00 | — | — |
Q2 2024 | May 1, 2024 | — | $0.00 | — | — |
Q1 2024 | Mar 29, 2024 | — | $0.05 | — | — |
Q4 2023 | Dec 26, 2023 | — | $0.05 | — | — |
Q3 2023 | Aug 31, 2023 | $0.05 | $0.03 | -40.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $0.08 | $0.01 | -87.5% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $0.05 | — | — |
Q4 2022 | Nov 15, 2022 | $0.32 | $0.05 | -84.4% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $0.26 | $0.10 | -61.5% | ✗ MISS |
Q2 2022 | May 16, 2022 | $0.24 | $0.11 | -54.2% | ✗ MISS |
Q2 2022 | Apr 6, 2022 | $0.14 | $-0.02 | -114.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $0.15 | $-0.01 | -106.7% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $0.14 | $0.12 | -14.3% | ✗ MISS |
Q2 2021 | May 10, 2021 | — | $0.04 | — | — |
Latest News
InterCure Enters Into Definitive Share Purchase Agreement And Collaboration Agreement With Cannasoul To Advance Cannabis Science And Pharmaceutical Innovation
📈 PositiveBenzinga•Nov 3, 2025, 01:43 PM
Intercure H1 EPS $0.01 Up From $0.00 YoY, Sales $36.292M Miss $66.530M Estimate
📉 NegativeBenzinga•Oct 9, 2025, 08:32 AM
InterCure Acquires Botanico (aka ISHI) In All-Stock Deal Worth 4.92M Ordinary Shares To Expand Cannabis Portfolio
📈 PositiveBenzinga•Sep 19, 2025, 12:51 PM
Frequently Asked Questions about INCR
What is INCR's current stock price?
InterCure Ltd. (INCR) is currently trading at $1.36 per share. The stock has moved -6.21% today.
What is the analyst price target for INCR?
No analyst price targets are currently available for this stock.
What sector is InterCure Ltd. in?
InterCure Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is INCR's market cap?
InterCure Ltd. has a market capitalization of $0.07 billion, making it a small-cap company.
Does INCR pay dividends?
No, InterCure Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMWL
American Well Corporation
$4.66
Mkt Cap: $0.1B
ASRT
Assertio Holdings, Inc.
$0.72
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
CRDL
Cardiol Therapeutics Inc.
$1.01
Mkt Cap: $0.1B
EDAP
Edap Tms S.a.
$2.94
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
HYFT
MindWalk Holdings Corp.
$1.67
Mkt Cap: $0.1B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
Explore stocks similar to INCR for comparison